Department of Health and Human Services
National Institutes of Health
Toggle navigation
Search
Home
About the Clinical Center
Clinical Trials & You
Participate in a Study
Referring a Patient
How to Search
Contact Us
Search the Studies
Go Back
Searched Result
60 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Protocol Number
Title
Protocol Status
Min-Max Age
Institute
Keywords
001619-H
A Phase I Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects with Stable Sickle Cell Disease
Recruitment has not started
18-65 Years
NHLBI
Sickle Anemia
001061-H
Observational Study Investigating the Mechanistic Effects of Mitapivat in Subjects with Sickle Cell Disease
Enrolling by Invitation
16-125 Years
NHLBI
Sickle Anemia
000539-H
Addition of JSP191 (c-kit antibody) to Non-myeloablative Hematopoietic Cell Transplantation For Sickle Cell Disease and Beta-Thalassemia
Participants currently recruited/enrolled
4-100 Years
NHLBI
Sickle Anemia
000464-H
Evaluation of Clonal Hematopoiesis in Patients with Sickle Cell Disease Receiving Curative Therapies
Enrolling by Invitation
4-125 Years
NHLBI
Sickle Anemia
000423-C
Feasibility and Preliminary Efficacy of Acceptance and Commitment Therapy (ACT) for Sleep Disturbances in Adults with Sickle Cell Disease (SCD): A Pilot Randomized Controlled Trial
Participants currently recruited/enrolled
18-55 Years
NCI
Sickle Anemia
000049-H
Evaluation of the Safety,Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects with Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat
No longer recruiting/follow-up only
18-70 Years
NHLBI
Sickle Anemia
20-H-0080
Red Cell Half Life Determination in Patients with and without Sickle Cell Disease
Completed Study; data analyses ongoing
18-99 Years
NHLBI
Sickle Anemia
16-I-0065
Screening for Alpha Globin Deletions
Participants currently recruited/enrolled
18-39 Years
NIAID
Sickle Anemia
09-H-0225
Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia
No longer recruiting/follow-up only
2-100 Years
NHLBI
Sickle Anemia
08-DK-0004
High Sensitivity Screening of Compound Libraries to Discover a Drug for the Treatment of Sickle Cell Disease
Participants currently recruited/enrolled
18-100 Years
NIDDK
Sickle Anemia
03-H-0170
Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease (SCD) and B-Thalassemia
No longer recruiting/follow-up only
2-80 Years
NHLBI
Sickle Anemia
01-H-0088
Determining the Prevalence and Prognosis of Secondary Pulmonary Hypertension in Adult Patients with Sickle Cell Anemia
Completed Study; data analyses ongoing
18-125 Years
NHLBI
Sickle Anemia
001667-H
A Phase I/II Study of the JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure
Recruitment has not started
18-99 Years
NHLBI
Anemia
001635-H
Non-myeloablative Phase I/II Haploidentical HCT Study for Patients with Sickle Cell Disease, Including Compromised Organ Function
Recruitment has not started
4-100 Years
NHLBI
Sickle
001528-H
A Phase I/II, Intra-Patient Dose-Escalation Study of the Selective GlyT1 Inhibitor, Bitopertin for Steroid-Refractory Diamond-Blackfan Anemia.
Participants currently recruited/enrolled
18-100 Years
NHLBI
Anemia
001109-C
Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia
Participants currently recruited/enrolled
8-125 Years
NCI
Anemia
000844-H
Exploring Near Infrared Spectroscopy (NIRS) Technologies for Assessment of Muscle Physiology, Tissue Oxygenation, and Blood Flow in Patients with Sickle Cell Disease (SCD)
Participants currently recruited/enrolled
18-125 Years
NHLBI
Sickle
000760-H
Extension Study (extended access) of Syk-inhibition Using Fostamatinib to Treat Post-Transplant Immune-mediated Cytopenias
Enrolling by Invitation
18-75 Years
NHLBI
Anemia
000758-H
A Phase II Study Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-Mediated Cytopenias
Participants currently recruited/enrolled
18-75 Years
NHLBI
Anemia
000697-H
U01 Cooperative Assessment of Late Effects for SCD Curative Therapies (COALESCE)
Participants currently recruited/enrolled
18-65 Years
NHLBI
Sickle
000518-CC
Observational Study of Dietary Intake and Dietary Behaviors in Adults with Sickle Cell Disease
Participants currently recruited/enrolled
18-120 Years
CC
Sickle
000479-H
Observational Study to Deeply Phenotype Major Organs in Sickle Cell Disease After Curative Therapies
Participants currently recruited/enrolled
18-100 Years
NHLBI
Sickle
000387-H
The Natural History of Acquired and Inherited Bone Marrow Failure Syndromes.
Participants currently recruited/enrolled
2-125 Years
NHLBI
Anemia
20-H-0141
Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector
Enrolling by Invitation
18-125 Years
NHLBI
Sickle
20-H-0137
A Study to Evaluate the Effects of Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects with Stable Sickle Cell Disease
Completed Study; data analyses ongoing
18-70 Years
NHLBI
Sickle
20-H-0068
Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell Trait
Participants currently recruited/enrolled
18-80 Years
NHLBI
Sickle
20-H-0033
Early Initiation of Oral Therapy with Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)
Participants currently recruited/enrolled
3-99 Years
NHLBI
Anemia
20-H-0021
Treatment of Refractory Diamond-Blackfan Anemia with Eltrombopag
No longer recruiting/follow-up only
2-99 Years
NHLBI
Anemia
19-I-0093
Collection of Human Biospecimens for Basic and Clinical Research into Globin Variants
Participants currently recruited/enrolled
18-70 Years
NIAID
Sickle
19-H-0118
Repeat Peripheral Blood Stem Cell Transplantation for Patients with Sickle Cell Disease or Beta-Thalassemia and Falling Donor Myeloid Chimerism Levels
Participants currently recruited/enrolled
2-80 Years
NHLBI
Sickle
19-H-0100
Best Noninvasive Predictor of Renal Function in Assessing Adult Sickle Nephropathy
Completed Study; data analyses ongoing
18-125 Years
NHLBI
Sickle
19-H-0097
A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Multiple Oral Doses of AG-348 in Subjects with Stable Sickle Cell Disease
Completed Study; data analyses ongoing
18-70 Years
NHLBI
Sickle
18-H-0146
Genotype -Phenotype Correlation of PKLR Variants with Pyruvate Kinase, 2,3-Diphosphglycerate and ATP Activities in Red Blood Cells of Patients with Sickle Cell Disease
Participants currently recruited/enrolled
18-80 Years
NHLBI
Sickle
18-H-0090
Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH using Peripheral Blood Stem Cells and post-transplant Cyclophosphamide for GVHD prophylaxis
Participants currently recruited/enrolled
4-75 Years
NHLBI
Anemia
18-H-0004
Low Dose Danazol for the Treatment of Telomere Related Diseases
Participants currently recruited/enrolled
3-99 Years
NHLBI
Anemia
17-H-0124
Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) Patients Using Plerixafor
Completed Study; data analyses ongoing
18-125 Years
NHLBI
Sickle
17-H-0121
Eltrombopag for Patients with Fanconi Anemia
Participants currently recruited/enrolled
2-99 Years
NHLBI
Anemia
17-H-0091
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS using CordIn, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, to Expedite Engraftment and Improve Transplant Outcome
Participants currently recruited/enrolled
4-75 Years
NHLBI
Anemia
17-H-0069
Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease
No longer recruiting/follow-up only
2-100 Years
NHLBI
Sickle
17-H-0056
Pathophysiology of Acute Pain in Patients with Sickle Cell Disease
Completed Study; data analyses ongoing
18-80 Years
NHLBI
Sickle
17-H-0019
A Randomized Trial of Sirolimus (Rapamune(R)) for Relapse Prevention in Patients with Severe Aplastic Anemia Responsive to Immunosuppressive Therapy
Participants currently recruited/enrolled
2-99 Years
NHLBI
Anemia
14-HG-0125
Insights Into Microbiome and Environmental Contributions to Sickle Cell Disease and Leg Ulcers
Participants currently recruited/enrolled
18-125 Years
NHGRI
Sickle
14-H-0155
A Phase 1/2 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the LentiGlobin BB305 Lentiviral Vector in Subjects with Severe Sickle Cell Disease
No longer recruiting/follow-up only
18-50 Years
NHLBI
Sickle
14-H-0077
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia in Individuals with Higher Risk of Transplant Failure
Participants currently recruited/enrolled
4-80 Years
NHLBI
Sickle
13-H-0133
Extended Dosing with Eltrombopag in Refractory Severe Aplastic Anemia
Completed Study; data analyses ongoing
2-99 Years
NHLBI
Anemia
13-H-0116
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
Participants currently recruited/enrolled
4-125 Years
NHLBI
Anemia
12-H-0150
Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia
Participants currently recruited/enrolled
2-99 Years
NHLBI
Anemia
12-H-0064
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications
Participants currently recruited/enrolled
4-75 Years
NHLBI
Anemia
12-C-0160
Validation of the English Version of the Pain Interference Index and the Pain Rating Scale in Children, Adolescents, and Adults with Chronic Illness and their Parents
Completed Study; data analyses ongoing
18-125 Years
NCI
Sickle
11-H-0209
Male Hormones for Telomere Related Diseases
Completed Study; data analyses ongoing
2-99 Years
NHLBI
Anemia
11-H-0134
A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Moderate Aplastic Anemia Patients
No longer recruiting/follow-up only
2-99 Years
NHLBI
Anemia
10-H-0154
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused with a Reduced Dose of Non-Mobilized Donor T-Cells
Participants currently recruited/enrolled
4-80 Years
NHLBI
Anemia
08-H-0046
Co-Infusion of Umbilical Cord Blood and Haploidentical CD34+ Cells Following Nonmyeloablative Conditioning as Treatment for Severe Aplastic Anemia and MDS Associated with Severe Neutropenia Refractory to Immunosuppressive Therapy
Completed Study; data analyses ongoing
4-75 Years
NHLBI
Anemia
07-H-0113
Procurement and Analysis of Blood, Bone Marrow, and Buccal Mucosa Samples from Healthy Volunteers to Support Clinical and Translational Research Projects in the NHLBI
Participants currently recruited/enrolled
8-125 Years
NHLBI
Anemia
06-H-0190
Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders with Alemtuzumab (Campath)
Completed Study; data analyses ongoing
18-85 Years
NHLBI
Anemia
04-H-0161
Studies of the Natural History of Sickle Cell Disease
Participants currently recruited/enrolled
2-90 Years
NHLBI
Sickle
03-H-0015
Human Specimen Collection to Support Basic and Clinical Research
Participants currently recruited/enrolled
18-100 Years
NHLBI
Sickle
02-C-0052
Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes: A Natural History Study
Participants currently recruited/enrolled
0-125 Years
NCI
Anemia
01-H-0122
Collection and Storage of Umbilical Cord Hematopoietic Stem Cells for Sickle Cell Disease Therapy
Participants currently recruited/enrolled
18-45 Years
NHLBI
Sickle
97-H-0041
Screening Protocol for Subjects Being Evaluated for National Heart, Lung and Blood Institute (NHLBI) Protocols
Enrolling by Invitation
2-100 Years
NHLBI
Anemia